ClinicalTrials.gg
CompletedNCT01890473Updated Nov 26, 2015Results posted

Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

A Phase 1 interventional study of Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-26.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
17th of 63
356 · median 119
Started
2013
with 4 others
Phase 1
8 of 63
none open now
Registered
37th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is one of 5 that started in 2013, is one of 8 in phase 1, and was the 37th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.

Read the detailed description

SC=Subcutaneous

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects ≥18 years of age
  • Diagnosis of Rheumatoid Arthritis confirmed by participant's physician
  • Disease activity under control

Key Exclusion Criteria:

  • Change in disease-modifying antirheumatic drug (DMARD) therapy within 3 months of enrollment
  • Exposure to drug within 4 weeks or 5 half lives whichever is longer
  • Current or prior use of Rituximab ≤6 months
  • Current or prior use of the following within 4 weeks or 5 half lives whichever is longer: biologic DMARDS, Tofacitinib, Cyclophosphamide, Mycophenolate Mofetil \& d-Penicillamine
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    Arm 1: Abatacept (autoinjector)

    Abatacept 125 mg/syringe subcutaneously through autoinjector, one dose in 71 days

    Drug: Abatacept

  • Experimental
    Arm 2: Abatacept (prefilled syringe)

    Abatacept 125 mg/syringe subcutaneously with prefilled syringe, one dose in 71 days

    Drug: Abatacept

Interventions

  • Also known as: Orencia, BMS-188667

06

What researchers measure

Primary outcomes

  1. Adjusted Geometric Mean of Maximum Observed Serum Concentration (Cmax) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population

    Serum concentrations of abatacept were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was measured in micrograms per milliliter (μg/mL). Blood samples for pharmacokinetic (PK) parameters were collected at Day 1 pre-dose at 0 hour (h), 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC.

    Time frame: Day 1 to Day 71

  2. Adjusted Geometric Mean of Area Under the Serum Concentration-time Curve (AUC) From Zero to the Last Time of the Last Quantifiable Concentration (0-T) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

    Serum concentrations of abatacept were analyzed using ELISA. AUC (0-T) was measured in μg\*h/mL. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC.

    Time frame: Day 1 to Day 71

  3. Adjusted Geometric Mean of Area Under the Serum Concentration-time Curve From Time Zero to Extrapolated to Infinity, AUC (INF), of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

    Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 hour (h), 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. AUC (INF) was measured in μg\*h/mL

    Time frame: Day 1 to Day 71

Secondary outcomes

  1. Median of Time to Reach Cmax in Serum (Tmax) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

    Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. Tmax was measured in hours (h).

    Time frame: Day 1 to Day 71

  2. Mean of Terminal Phase Elimination Half-life in Serum (T-HALF) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

    Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. T-HALF was measured in hours (h).

    Time frame: Day 1 to Day 71

  3. Geometric Mean of Total Body Clearance (CL/F) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

    Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. CL/F was measured in milliliters per hour per kilogram body weight (mL/h/kg).

    Time frame: Day 1 to Day 71

  4. Geometric Mean of Volume of Distribution (V/F) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population

    Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. V/F was measured in liters per kilogram body weight (L/kg)

    Time frame: Day 1 to Day 71

  5. Number of Participants Who Had Serious Adverse Events (SAEs), Adverse Events (AEs) That Led to Discontinuation, or Who Died

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Includes data Day 1 up to 76 days (71 days + 5 day window) post the single dose of study drug.

    Time frame: Day 1 to 76 days post single dose

  6. Number of Participants With Adverse Events of Special Interest

    Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Infections, Autoimmune Disorders, Malignancy, local site reactions, any AE occurring within 24 hours of SC injection. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Day 1 to 76 days post single dose

  7. Number of Participants With a Positive Immunogenicity Response Relative to Baseline

    Blood samples were screened at baseline, Day 57 and Day 71 for the presence of drug-specific antibodies using Electrochemiluminescence (ECL). A positive immunogenicity response relative to baseline for Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4) and 'possibly immunoglobulin (Ig)', and 'Ig and/or Junction Region', respectively, was defined as: A missing baseline immunogenicity measurement and a positive analytical laboratory reported immunogenicity response post-baseline; A negative baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline; A positive baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline that has a titer value strictly greater than the baseline titer value. Baseline=Pre-dose value.

    Time frame: Day 57, Day 71

  8. Number of Participants With Blood Hematology, Chemistry Laboratory Values and Urinalysis Laboratory Values Meeting the Marked Abnormality Criteria

    Marked abnormality criteria: lower limit of normal (LLN); upper limit of normal (ULN); pretreatment (preRX); cells per microliter (cµ/L); milligram per deciliter (mg/dL); milliequivalent (mEq): Hematology: leukocytes (\*10\^3 c/µL): \<0.75\*LLN or \>1.25\*ULN, or if preRX \<LLN, use \<0.8\*preRX or \>ULN, or if preRX\>ULN, use \>1.2\*preRX or \<LLN; eosinophils (\*10\^3 cµ/L): if value \>0.750\*10\^3 c/µL; lymphocytes (\*10\^3 cµ/L): if value \<0.750\*10\^3 c/µL or if value \>7.50\*10\^3 c/µL. Chemistry: blood urea nitrogen (mg/dL): \>2\*preRX; creatinine (mg/dL): \>1.5\*preRX; potassium (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRX\<LLN, use \<0.9\*preRX or \>ULN, or if preRX\>ULN, use 1.1\*preRX or \<LLN; glucose (mg/dL): \<65 mg/dL (low) or \>220 mg/dL (high). Urine Blood, urine red blood cell (RBC), urine white blood cell (WBC): if missing PreRX use \>= 2, or if Value \>= 4, or if preRX = 0 or 0.5 then use \>= 2, or if preRX = 1 then use \>= 3, or if preRX = 2 or 3 then use \>= 4.

    Time frame: Day 1 to 76 days post last dose

07

Results

Posted Nov 26, 2015

Participant flow

Participant flow — Overall Study
Milestone125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Started111113
Completed109113
Not completed20
Withdrew: Lost to follow-up10
Withdrew: Poor/non-compliance10

Outcome measures

PrimaryAdjusted Geometric Mean of Maximum Observed Serum Concentration (Cmax) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population

Serum concentrations of abatacept were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was measured in micrograms per milliliter (μg/mL). Blood samples for pharmacokinetic (PK) parameters were collected at Day 1 pre-dose at 0 hour (h), 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC.

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · μg/mL
Adjusted Geometric Mean of Maximum Observed Serum Concentration (Cmax) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population
μg/mL125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Adjusted Geometric Mean of Maximum Observed Serum Concentration (Cmax) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population11.5 (10.6 to 12.4)12.6 (11.7 to 13.6)
Statistical analysis
  • 125 mg Abatacept Via Autoinjector vs 125 mg Abatacept Via Prefilled Syringe · Ratio of geometric mean: 0.908 · 90% CI 0.815 to 1.01
PrimaryAdjusted Geometric Mean of Area Under the Serum Concentration-time Curve (AUC) From Zero to the Last Time of the Last Quantifiable Concentration (0-T) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

Serum concentrations of abatacept were analyzed using ELISA. AUC (0-T) was measured in μg\*h/mL. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC.

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · μg*h/mL
Adjusted Geometric Mean of Area Under the Serum Concentration-time Curve (AUC) From Zero to the Last Time of the Last Quantifiable Concentration (0-T) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population
μg*h/mL125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Adjusted Geometric Mean of Area Under the Serum Concentration-time Curve (AUC) From Zero to the Last Time of the Last Quantifiable Concentration (0-T) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population4991 (4613 to 5400)5304 (4913 to 5727)
Statistical analysis
  • 125 mg Abatacept Via Autoinjector vs 125 mg Abatacept Via Prefilled Syringe · Ratio of geometric mean: 0.941 · 90% CI 0.843 to 1.05
PrimaryAdjusted Geometric Mean of Area Under the Serum Concentration-time Curve From Time Zero to Extrapolated to Infinity, AUC (INF), of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 hour (h), 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. AUC (INF) was measured in μg\*h/mL

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · μg*h/mL
Adjusted Geometric Mean of Area Under the Serum Concentration-time Curve From Time Zero to Extrapolated to Infinity, AUC (INF), of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population
μg*h/mL125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Adjusted Geometric Mean of Area Under the Serum Concentration-time Curve From Time Zero to Extrapolated to Infinity, AUC (INF), of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population5308 (4957 to 5684)5437 (5089 to 5810)
Statistical analysis
  • 125 mg Abatacept Via Autoinjector vs 125 mg Abatacept Via Prefilled Syringe · Ratio of geometric mean: 0.976 · 90% CI 0.888 to 1.07
SecondaryMedian of Time to Reach Cmax in Serum (Tmax) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. Tmax was measured in hours (h).

Time frame:
Day 1 to Day 71
Reported as:
Median · h
Median of Time to Reach Cmax in Serum (Tmax) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population
h125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Median of Time to Reach Cmax in Serum (Tmax) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population96.0 (24 to 337)96.0 (24 to 336)
SecondaryMean of Terminal Phase Elimination Half-life in Serum (T-HALF) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. T-HALF was measured in hours (h).

Time frame:
Day 1 to Day 71
Reported as:
Mean · h
Mean of Terminal Phase Elimination Half-life in Serum (T-HALF) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population
h125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Mean of Terminal Phase Elimination Half-life in Serum (T-HALF) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population285 ± 89.54302 ± 99.82
SecondaryGeometric Mean of Total Body Clearance (CL/F) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population

Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. CL/F was measured in milliliters per hour per kilogram body weight (mL/h/kg).

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · mL/h/kg
Geometric Mean of Total Body Clearance (CL/F) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population
mL/h/kg125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Geometric Mean of Total Body Clearance (CL/F) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population0.31 ± 520.30 ± 62
SecondaryGeometric Mean of Volume of Distribution (V/F) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population

Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. V/F was measured in liters per kilogram body weight (L/kg)

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · L/kg
Geometric Mean of Volume of Distribution (V/F) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population
L/kg125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Geometric Mean of Volume of Distribution (V/F) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population0.12 ± 430.12 ± 62
SecondaryNumber of Participants Who Had Serious Adverse Events (SAEs), Adverse Events (AEs) That Led to Discontinuation, or Who Died

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Includes data Day 1 up to 76 days (71 days + 5 day window) post the single dose of study drug.

Time frame:
Day 1 to 76 days post single dose
Reported as:
Number · participants
Number of Participants Who Had Serious Adverse Events (SAEs), Adverse Events (AEs) That Led to Discontinuation, or Who Died
participants125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Death00
SAE01
Related SAEs00
Discontinued due to AE00
SecondaryNumber of Participants With Adverse Events of Special Interest

Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Infections, Autoimmune Disorders, Malignancy, local site reactions, any AE occurring within 24 hours of SC injection. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Day 1 to 76 days post single dose
Reported as:
Number · participants
Number of Participants With Adverse Events of Special Interest
participants125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Infections1917
Autoimmune Disorders00
Malignancy00
Local site reactions13
AEs within 24 hours of SC injection107
SecondaryNumber of Participants With a Positive Immunogenicity Response Relative to Baseline

Blood samples were screened at baseline, Day 57 and Day 71 for the presence of drug-specific antibodies using Electrochemiluminescence (ECL). A positive immunogenicity response relative to baseline for Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4) and 'possibly immunoglobulin (Ig)', and 'Ig and/or Junction Region', respectively, was defined as: A missing baseline immunogenicity measurement and a positive analytical laboratory reported immunogenicity response post-baseline; A negative baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline; A positive baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline that has a titer value strictly greater than the baseline titer value. Baseline=Pre-dose value.

Time frame:
Day 57, Day 71
Reported as:
Number · participants
Number of Participants With a Positive Immunogenicity Response Relative to Baseline
participants125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Day 57 CTLA4, possibly Ig (n=109,111)1013
Day 57 Ig and/or junction (n=109,111)45
Day 71 CTLA4, possibly Ig (n=105,112)2322
Day 71 Ig and/or junction (n=105,112)15
Overall CTLA4, possibly Ig (n=109,113)2424
Overall Ig and/or junction (n=109,113)48
SecondaryNumber of Participants With Blood Hematology, Chemistry Laboratory Values and Urinalysis Laboratory Values Meeting the Marked Abnormality Criteria

Marked abnormality criteria: lower limit of normal (LLN); upper limit of normal (ULN); pretreatment (preRX); cells per microliter (cµ/L); milligram per deciliter (mg/dL); milliequivalent (mEq): Hematology: leukocytes (\*10\^3 c/µL): \<0.75\*LLN or \>1.25\*ULN, or if preRX \<LLN, use \<0.8\*preRX or \>ULN, or if preRX\>ULN, use \>1.2\*preRX or \<LLN; eosinophils (\*10\^3 cµ/L): if value \>0.750\*10\^3 c/µL; lymphocytes (\*10\^3 cµ/L): if value \<0.750\*10\^3 c/µL or if value \>7.50\*10\^3 c/µL. Chemistry: blood urea nitrogen (mg/dL): \>2\*preRX; creatinine (mg/dL): \>1.5\*preRX; potassium (mEq/L): \<0.9\*LLN or \>1.1\*ULN, or if preRX\<LLN, use \<0.9\*preRX or \>ULN, or if preRX\>ULN, use 1.1\*preRX or \<LLN; glucose (mg/dL): \<65 mg/dL (low) or \>220 mg/dL (high). Urine Blood, urine red blood cell (RBC), urine white blood cell (WBC): if missing PreRX use \>= 2, or if Value \>= 4, or if preRX = 0 or 0.5 then use \>= 2, or if preRX = 1 then use \>= 3, or if preRX = 2 or 3 then use \>= 4.

Time frame:
Day 1 to 76 days post last dose
Reported as:
Number · participants
Number of Participants With Blood Hematology, Chemistry Laboratory Values and Urinalysis Laboratory Values Meeting the Marked Abnormality Criteria
participants125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Leukocytes High (n=109, 110)10
Leukocytes Low (n=109, 110)01
Eosinophils High (n=107,107)10
Lymphocytes Low (n=107,107)25
Blood Urea Nitrogen High (n=109,111)10
Creatinine High (n=109,111)20
Potassium Low (n=109,111)01
Glucose High (n=109,110)20
Glucose Low (n=109,110)33
Urine Blood High (n=104,107)71
Urine RBC High (n=28, 26)52
Urine WBC High (n=35, 33)1113

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
125 mg Abatacept Via Autoinjector—0/111 (0%)0/111 (0%)
125 mg Abatacept Via Prefilled Syringe—1/113 (0.9%)0/113 (0%)
Most frequent serious events
Most frequent serious events
Event125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled Syringe
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/1111/113

Baseline characteristics

All randomized participants were summarized.

Age, Continuous
Age, Continuous(years)125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled SyringeTotal
Mean53.0 ± 13.3456.8 ± 12.3654.9 ± 12.97
Age, Customized
Age, Customized(participants)125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled SyringeTotal
Less than (<) 659075165
Greater than, equal to (>=) 65213859
Sex: Female, Male
Sex: Female, Male(Participants)125 mg Abatacept Via Autoinjector125 mg Abatacept Via Prefilled SyringeTotal
Female9087177
Male212647
08

Study locations

25 sites
  • Rheumatology Associates Of North Alabama, P.C.
    Huntsville, Alabama 35801, United States
  • Immunoe Int'L Research Ctrs
    Centennial, Colorado 80112, United States
  • Covance Cru Inc
    Daytona Beach, Florida 32117, United States
  • Heartland Research Associates, Llc
    Wichita, Kansas 67207, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Physician Research Collaboration, Llc
    Lincoln, Nebraska 68516, United States
  • Djl Research, Pllc
    Charlotte, North Carolina 28210, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Pmg Research Of Salisbury
    Salisbury, North Carolina 28144, United States
  • Pmg Research Of Wilmington Llc
    Wilmington, North Carolina 28401, United States
  • Community Research
    Cincinnati, Ohio 45255, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Covance Clinical Research Unit Inc.
    Dallas, Texas 75247, United States
  • Local Institution
    San Fernando, Buenos Aires 1646, Argentina
  • Local Institution
    Rosario, Santa Fe 2000, Argentina
  • Local Institution
    San Miguel De Tucuman, Tucuman 4000, Argentina
  • Local Institution
    Cordoba, 5000, Argentina
  • Local Institution
    Cordoba, 5016, Argentina
  • Local Institution
    Yucatan, 97000, Mexico
  • Local Institution
    Lima, 33, Peru
  • Local Institution
    Lima, LIMA 01, Peru
  • Local Institution
    Port Elizabeth, Eastern Cape 6001, South Africa
  • Local Institution
    Pretoria, Gauteng 0122, South Africa
  • Local Institution
    Pretoria, Gauteng 0184, South Africa
  • Local Institution
    George, Western Cape 6529, South Africa
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2013
First posted
Jul 1, 2013
Start
Jul 2013
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Nov 26, 2015
Last update
Nov 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01890473
Responsible party
Sponsor
First posted
Jul 1, 2013
Start date
Jul 2013
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Nov 26, 2015
Last update
Nov 26, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion